Selective estrogen receptor downregulators (SERDs)

Fulvestrant      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

fulvestrant
GEICAM/2006-10fulvestrant + anastrozoleanastrozole HER-2 negative HR positive postmenopausal NCT00543127 -
FACT (Bergh), 2012fulvestrant + anastrozoleanastrozole first line of endocrine therapy HR positive postmenopausal NCT00256698negative
Mehta(SWOG-S0226), 2012fulvestrant + anastrozoleanastrozole HR positive NCT00075764suggesting
CDR0000349337 ongoing fulvestrant + anastrozoleanastrozole first line of endocrine therapy postmenopausal NCT00075764 ongoing
Xu et al., 2011fulvestrant 250mganastrozole HR positive postmenopausal NCT00327769 -
0021 (Osborne), 2002fulvestrant 250mganastrozole postmenopausal NCT00635713negative
0020 (Howell), 2002fulvestrant 250mganastrozolenegative
A011106 ongoing fulvestrant 250mganastrozoleNCT01953588 ongoing
FIRST (Robertson), 2010fulvestrant 500mganastrozole first line of endocrine therapy postmenopausal NCT00274469suggesting
FALCON ongoing fulvestrant 500mganastrozole first line of endocrine therapy NCT01602380 ongoing
FUMANCE ongoing fulvestrant 500mgcontrol maintenance therapy postmenopausal NCT02383030 ongoing
9238UK/0005 (fluvestrant alone)fluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy NCT00944918 -
SoFEa (Johnston) fluvestrant alone, 2012fluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy NCT00253422 -
9238UK/0005 (combination)fulvestrant + anastrozoleexemestane postmenopausal previously treated with endocrine therapy NCT00944918 -
SoFEa (Johnston) combination, 2012fulvestrant + anastrozoleexemestane HR positive postmenopausal previously treated with endocrine therapy NCT00253422negative
EFECT (Chia)fulvestrant 250mgexemestane HR positive postmenopausal NCT00065325negative
D6997L00021fulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy NCT01300351 -
CONFIRM (Di Leo), 2010fulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy NCT00099437 -
FINDER 1 (Ohno), 2010fulvestrant 500mgfulvestrant 250mg postmenopausal -
FINDER 2, 2010fulvestrant 500mgfulvestrant 250mg postmenopausal previously treated with endocrine therapy NCT00313170Exploratory -
9238IL/0025fulvestrant 250mgtamoxifen first line of endocrine therapy NCT00241449 -
0025 (Howell), 2004fulvestrant 250mgtamoxifen previously treated with endocrine therapy negative